Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Based on this commitment, we have developed Q360+
Retatrutide, a triple agonist targeting gastric inhibitory polypeptide (GIP), GLP-1, and glucagon receptors, has achieved highly promising outcomes in its phase 2 trial [22], with weight loss up to 24%
Explications avec le Dr
Potential Benefits for Diabetes Management While primarily tested for weight loss, its triple receptor activation could make it even more effective for blood sugar control than tirzepatide (Mounjaro), which already outperforms older diabetes medications
Tirzepatide achieves 20.9% at 72 weeks on 15mg, per SURMOUNT-1 (Jastreboff et al., NEJM 2022)
Ongoing monitoring for any unexpected effects remains prudent
US$ 28.10
US$ 20.48
US$ 26.66
US$ 24.26
US$ 22.49
US$ 21.29
US$ 26.55
